UNSPSC 51282410: Temocillin

This classification denotes a penicillin antibiotic with the molecular formula C16H18N2O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03QB156W6I, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-6-methoxy-3,3-dimethyl-7-oxo-, (2s-(2alpha,5alpha,6alpha))- but generally known as temocillin, which bears US NIH Compound Identifier 171758.

UNSPSC 51282410 Temocillin, a Commodity code, shows a significant mismatch between its nominal scope and recent state and local procurement activity. The code nominally identifies a specific antibiotic pharmaceutical ingredient, yet the recent opportunities posted under this code encompass a much broader range of pharmaceutical and medical supply procurement — including naloxone, drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and emergency medical supplies for first responders. State and local buyers using this code are acquiring finished pharmaceutical products, medical consumables, and emergency-response supplies rather than the specific active pharmaceutical ingredient the code name suggests. Issuing bodies include county health departments, state health and human services commissions, municipal fire departments, and multi-state cooperative purchasing alliances.

Recent activity spans Florida, Texas, Minnesota, Oregon, and the broader multistate cooperative purchasing network. Representative opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000 (due March 13, 2026, with a sheltered-market set-aside for certified Small Local Business Enterprises), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon (due March 26, 2026). The Texas Health and Human Services Commission also posted an RFI in April 2026 exploring direct-to-manufacturer prescription programs. The code shows little relevant recent activity aligned with its stated pharmaceutical ingredient scope.